

The Global Magazine for
the Pharmaceutical and
Biopharmaceutical Industry

Pharma

[Home](#)

[About Us](#)

[Contact Us](#)

[Home](#)

[News](#)

[White Papers](#)

[Latest events](#)

[Buyers' Guide](#)

[Media kit](#)

[List Rental](#)

[Magazine issues](#)

[Submit editorial](#)

[Outsourcing Awards](#)

[Subscribe](#)

[Via TV](#)

[Careers](#)

[Market watch](#)



The global magazine for the pharmaceutical
biopharmaceutical industry

WIL Research Laboratories Acquires Midwest BioResearch

WIL Research Laboratories and WIL Research Holding Company have acquired Midwest BioResearch. Together, Midwest BioResearch and WIL Research shall integrate their service offerings through scientific collaboration, sharing of best practices and marketing.

Midwest BioResearch's significant expertise in immunoanalytical and bioassay techniques and small molecule bioanalysis, supporting both clinical and nonclinical research, and their expertise in genetic toxicology, complements WIL Research's contract research service offering. This includes expertise in chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry and metabolism.

Michael Schlosser, PhD, DABT, President and Founder of Midwest BioResearch, will continue to lead the existing Skokie, Illinois site reporting to Christopher P. Chengelis, PhD, DABT, Vice President and Chief Scientific Officer at WIL Research. Dr Schlosser has more than 20 years of experience within the pharmaceutical industry and 25 years of experience in toxicology.

"Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities," said Dr Chengelis. "We also benefit from a world-class staff with significant pharmaceutical and biotechnology industry experience and the addition of a program services consulting group."

In addition, Sal Guccione, Chief Executive Officer at WIL Research Holding Company, stated "that this transaction greatly enhances our capabilities to serve our clients in small and large molecule drug development. We are delighted to welcome this experienced team to the WIL family of research companies."



PHARMSOURCE